Tag: B cells

Approved by the FDA in 2017, Ocrevus (ocrelizumab) was the first disease-modifying therapy for primary progressive multiple sclerosis (PPMS) [1.10.2]. A common question is, **does Ocrevus weaken the immune system?** The short answer is yes, by design.

Originally developed to treat non-Hodgkin lymphoma, rituximab is now widely used for a variety of autoimmune diseases [1.2.1]. For patients, a critical question arises: **does rituximab weaken your immune system?** The answer is yes, and this effect is central to how it works.

After rituximab treatment, the body's B-cell levels are significantly depleted, with immune reconstitution typically beginning around six to nine months and often returning to pre-treatment levels within 12 months for many individuals. This means that **how long are you immunocompromised after rituximab** is not a simple question, as the duration can vary significantly based on individual factors and the underlying condition being treated.